# Vertex Pharmaceuticals (VRTX) Forecast Calculator

Interactive five-year financial forecast and DCF for Vertex Pharmaceuticals. Adjust revenue growth, margins, capex, and WACC to update revenue, free cash flow, and enterprise value.

- Canonical: https://finamodel.com/companies/vertex-pharmaceuticals/forecast
- Industry: Healthcare
- Forecast start year: 2026

## Historical data

| Year | Revenue | Free cash flow | EBITDA | Net income |
|---:|---:|---:|---:|---:|
| 2021 | 4162800000 | 1493900000 | 1304400000 | 1176800000 |
| 2022 | 6205700000 | 2993700000 | 2965800000 | 2711700000 |
| 2023 | 7574400000 | 2408500000 | 2907700000 | 2342100000 |
| 2024 | 8930700000 | 3925200000 | 4455700000 | 3322000000 |
| 2025 | 9869200000 | 3336900000 | 4013300000 | 3619600000 |

## Frequently asked questions

### What does Vertex Pharmaceuticals do?

Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and commercializing transformative medicines for people with serious diseases. It established its foundation by treating the underlying cause of cystic fibrosis and is now diversifying into gene therapy, non-opioid pain management, and autoimmune diseases.

### What are the primary revenue drivers for Vertex Pharmaceuticals?

Vertex Pharmaceuticals' revenue is predominantly driven by its Cystic Fibrosis franchise, which accounted for approximately 99% of its 2024 revenue. Future growth is anticipated from new product launches such as the gene therapy Casgevy and the acute pain medication Journavx.

### How does the Vertex Pharmaceuticals financial model account for new product launches?

The Vertex Pharmaceuticals financial model is designed to forecast the cash flow durability of the cystic fibrosis franchise while probability-weighting the commercial ramp of recent and upcoming launches. This includes products like Casgevy, Journavx, and povetacicept, enabling comprehensive equity valuation and pipeline scenario planning.

### What is Vertex Pharmaceuticals' capital expenditure strategy?

Vertex Pharmaceuticals' capital expenditure typically ranges from 2% to 3% of revenue, primarily consisting of growth capex. This investment supports the expansion of R&D laboratory footprints and the buildout of internal cell and genetic therapy manufacturing capabilities in the Boston area.

### Can I download an Excel financial model for Vertex Pharmaceuticals?

Yes, a comprehensive Excel financial model for Vertex Pharmaceuticals is available for download. This general corporate model provides an equity valuation and pipeline scenario planning tool with a forecast horizon from FY2026 to FY2030.

### How much does Vertex Pharmaceuticals invest in research and development?

Vertex Pharmaceuticals operates with an asset-light manufacturing model but makes significant investments in intellectual property and R&D. The financial model assumes R&D expenses at approximately 35% of revenue, reflecting its commitment to discovering and developing new medicines.